文献速递免疫规划传染病防控与疫情报告

NVX-CoV2373(TAK-019)疫苗在健康日本成人中的安全性和免疫原性:I/II期随机对照试验的中期报告

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
PubMed 文献 · Vaccine · 2022-04-29

这项在日本两个中心开展的I/II期随机观察者盲法安慰剂对照试验,纳入200名无SARS-CoV-2感染史/风险且未接触过其他SARS-CoV-2疫苗或治疗的健康日本成人(≥20岁),按年龄(<65岁或≥65岁)分层后随机接受两剂NVX-CoV2373(5 μg SARS-CoV-2 rS;50 μg Matrix-M1)或安慰剂,间隔21天。结果显示,NVX-CoV2373组接种后7天内征集性不良事件发生率为121/150(80.7%),安慰剂组为11/50(22.0%);结论认为两剂NVX-CoV2373间隔21天在健康日本成人中安全性可接受并诱导了稳健的抗SARS-CoV-2免疫应答。

要点

  • NVX-CoV2373组征集性不良事件发生率80.7%(121/150),安慰剂组22.0%(11/50)。

核心结论

  • 两剂NVX-CoV2373间隔21天在健康日本成人中显示可接受的安全性并诱导了稳健的抗SARS-CoV-2免疫应答。

研究设计与样本

  • I/II期随机、观察者盲法、安慰剂对照试验,在日本两个中心开展。
  • 纳入健康日本成人≥20岁,无SARS-CoV-2感染史/风险且未接触过其他已批准/在研SARS-CoV-2疫苗或治疗。
  • 按年龄(<65岁或≥65岁)分层随机,接受两剂NVX-CoV2373(5 μg SARS-CoV-2 rS;50 μg Matrix-M1)或安慰剂,间隔21天。
  • 共筛查326人,入组并随机200人:NVX-CoV2373组n=150,安慰剂组n=50。
  • 主要结局为安全性及第36天针对SARS-CoV-2 rS蛋白的血清IgG抗体水平;本次报告为第二剂后4周的主要数据分析(数据截止2021年5月8日)。

主要发现

  • 每次注射后7天内征集性不良事件:NVX-CoV2373组121/150(80.7%),安慰剂组11/50(22.0%)。
  • NVX-CoV2373组各年龄段每次接种后最常见征集性不良事件为压痛和注射部位疼痛。
  • 安慰剂组(n=49)未出现此类免疫应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants. METHODS: This phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021). RESULTS: Between 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49). CONCLUSION: Two doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. FUNDING: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). CLINICALTRIALS: gov identifier: NCT04712110.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Masuda T, Murakami K, Sugiura K, et al. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. Vaccine. 2022. PMID: 35501178. doi:10.1016/j.vaccine.2022.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。